Profile data is unavailable for this security.
About the company
Stella Pharma Corp is a Japan-based company mainly engaged in the therapeutic drug research and development. It is engaged in the research and development of boron drugs for boron neutron capture therapy (BNCT). BNCT is a radiation therapy that selectively destroys cancer cells by utilizing the fission reaction of B-10, which is a stable isotope of boron, and thermal neutrons with low energy. Nucleus of B-10, which is a stable isotope of boron, absorbs low-energy low-speed neutrons and immediately splits into a helium nucleus (4He nucleus (α particle)) and a lithium nuclei (7Li nuclei). When a substance containing B-10 selectively accumulates in cancer cells and is irradiated with thermal neutrons, cancer cells are selectively destroyed. Product includes steboronin (SPM-011). A phase II clinical trial is conducted for brain tumor, head and neck cancer and recurrent malignant glioma. Phase I clinical trial is started for malignant melanoma, a type of skin cancer, and angiosarcoma.
- Revenue in JPY (TTM)269.49m
- Net income in JPY-763.75m
- Incorporated2007
- Employees46.00
- LocationStella Pharma Corp3-2-7, Koraibashi, Chuo-kuOSAKA-SHI 541-0043JapanJPN
- Phone+81 647071516
- Fax+81 647072077
- Websitehttps://stella-pharma.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wakamoto Pharmaceutical Co Ltd | 7.98bn | -177.67m | 8.33bn | 292.00 | -- | 0.7089 | 35.80 | 1.04 | -5.12 | -5.12 | 229.89 | 337.15 | 0.525 | 2.08 | 2.88 | 27,324,600.00 | -1.17 | -2.58 | -1.34 | -3.00 | 46.98 | 53.08 | -2.23 | -4.33 | 3.45 | -- | 0.0085 | -- | 3.31 | -4.50 | -42.04 | 1.88 | -17.49 | 0.00 |
| CanBas Co Ltd (Parent) | 0.00 | -1.09bn | 8.76bn | 12.00 | -- | 2.93 | -- | -- | -64.47 | -64.47 | 0.00 | 166.10 | 0.00 | -- | -- | 0.00 | -43.91 | -65.86 | -45.99 | -79.11 | -- | -- | -- | -1,094.10 | -- | -- | 0.00 | -- | -- | -- | -45.41 | -- | -- | -- |
| TMS Co Ltd | 0.00 | -960.04m | 9.67bn | 14.00 | -- | 2.80 | -- | -- | -25.89 | -25.89 | 0.00 | 85.77 | 0.00 | -- | -- | -- | -26.14 | -- | -26.78 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -11.51 | -- | -- | -- |
| Tsubota Laboratory Inc | 673.53m | -641.32m | 9.82bn | 10.00 | -- | 7.18 | -- | 14.58 | -25.15 | -25.15 | 26.42 | 53.45 | 0.2711 | 2.04 | 37.74 | -- | -25.82 | -- | -36.41 | -- | 3.17 | -- | -95.22 | -- | 2.31 | -489.86 | 0.0788 | -- | -29.45 | -- | -811.14 | -- | -- | -- |
| Linical Co Ltd | 12.52bn | 680.40m | 10.14bn | 759.00 | 13.61 | 1.18 | 8.53 | 0.8102 | 30.12 | 30.12 | 554.28 | 346.38 | 0.7251 | -- | 3.99 | 16,494,230.00 | 3.94 | 4.71 | 6.55 | 7.23 | 33.10 | 31.60 | 5.43 | 5.98 | -- | 17,809.03 | 0.2793 | 45.36 | 8.32 | 6.55 | 27.06 | -4.97 | -33.01 | 4.94 |
| AnGes Inc | 249.94m | -6.35bn | 10.35bn | 145.00 | -- | 0.3696 | -- | 41.42 | -32.62 | -32.62 | 1.29 | 124.45 | 0.0077 | 0.0862 | 4.77 | 1,723,752.00 | -19.47 | -28.50 | -23.06 | -33.14 | 39.85 | 39.42 | -2,540.59 | -6,726.82 | 0.9124 | -- | 0.0139 | -- | 128.13 | -24.17 | 49.45 | -- | 12.11 | -- |
| 3-D Matrix Ltd | 3.74bn | -1.06bn | 10.69bn | 108.00 | -- | 16.91 | -- | 2.86 | -14.90 | -14.90 | 54.06 | 7.74 | 0.6653 | 0.4654 | 5.19 | 34,630,130.00 | -18.91 | -57.69 | -23.28 | -77.31 | 64.04 | 40.76 | -28.43 | -205.34 | 2.33 | -- | 0.8717 | -- | 53.63 | 58.87 | -29.09 | -- | -7.69 | -- |
| Stella Pharma Corp | 269.49m | -763.75m | 10.93bn | 46.00 | -- | 4.60 | -- | 40.55 | -24.63 | -24.63 | 8.70 | 76.12 | 0.0661 | 0.0508 | 3.98 | -- | -18.74 | -22.50 | -21.00 | -24.83 | 80.63 | -- | -283.40 | -488.65 | 5.52 | -379.39 | 0.2819 | -- | 17.65 | -- | 1.94 | -- | -5.87 | -- |
| KOEI CHEMICAL COMPANY, LIMITED | 19.43bn | 299.18m | 11.14bn | 387.00 | 37.16 | 0.5095 | 4.77 | 0.5733 | 61.17 | 61.17 | 3,971.90 | 4,460.94 | 0.4957 | 1.66 | 3.80 | -- | 0.7659 | 3.15 | 0.997 | 3.94 | 27.17 | 25.24 | 1.55 | 5.85 | 0.6907 | 115.66 | 0.3207 | 43.88 | 4.44 | 1.19 | -56.72 | -20.82 | -3.29 | 10.76 |
| Medinet Co Ltd | 711.82m | -1.40bn | 11.54bn | 98.00 | -- | 2.07 | -- | 16.21 | -6.00 | -6.00 | 3.03 | 21.73 | 0.124 | 11.34 | 3.78 | 7,263,510.00 | -24.31 | -21.05 | -25.48 | -22.47 | 15.25 | 28.75 | -196.06 | -135.40 | 20.08 | -- | 0.00 | -- | 4.40 | -7.90 | -14.66 | -- | -17.67 | -- |
| ReproCell Inc | 2.43bn | -31.42m | 11.64bn | 92.00 | -- | 1.39 | 153.32 | 4.79 | -0.3465 | -0.3465 | 28.34 | 93.45 | 0.2788 | 5.41 | 5.60 | -- | -0.3609 | -7.35 | -0.3932 | -8.00 | 46.19 | 39.83 | -1.29 | -27.16 | 10.54 | -- | -- | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
| Nano Mrna Co Ltd | 135.51m | -780.00m | 12.46bn | 17.00 | -- | 3.64 | -- | 91.95 | -11.10 | -11.10 | 1.93 | 48.61 | 0.025 | 59.02 | 9.66 | -- | -14.37 | -24.16 | -15.59 | -25.17 | 81.88 | 84.69 | -575.61 | -600.70 | 9.17 | -- | 0.2448 | -- | -32.98 | -22.88 | 40.50 | -- | -- | -- |
| RaQualia Pharma Inc | 1.90bn | -323.66m | 12.85bn | 67.00 | -- | 2.10 | -- | 6.76 | -14.99 | -14.99 | 87.98 | 283.05 | 0.2896 | 3.13 | 3.15 | 28,376,150.00 | -4.93 | 2.13 | -5.29 | 2.26 | 87.11 | 88.49 | -17.02 | 5.32 | 12.35 | -- | 0.0567 | 0.00 | -34.85 | 20.62 | -144.74 | -- | 0.0967 | -- |
| Healios KK | 124.00m | -5.52bn | 12.89bn | 64.00 | -- | 3.48 | -- | 103.94 | -72.60 | -72.60 | 1.70 | 41.05 | 0.0078 | -- | 0.3713 | 1,937,500.00 | -34.77 | -23.55 | -52.02 | -28.52 | 81.45 | -- | -4,440.32 | -6,580.16 | -- | -1.90 | 0.6824 | -- | 34.44 | -- | 26.04 | -- | -22.00 | -- |
| Oncolys Biopharma Inc | 28.04m | -1.98bn | 13.88bn | 34.00 | -- | 7.87 | -- | 494.92 | -107.77 | -107.77 | 1.52 | 84.14 | 0.0127 | 0.00 | 0.1476 | 824,647.10 | -89.46 | -45.75 | -101.52 | -51.86 | 100.00 | 60.46 | -7,058.44 | -233.66 | 8.82 | -- | 0.1416 | -- | -93.54 | -17.86 | -68.72 | -- | 28.18 | -- |
Data as of May 17 2024. Currency figures normalised to Stella Pharma Corp's reporting currency: Japanese Yen JPY
9.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nikko Asset Management Co., Ltd.as of 30 Dec 2022 | 2.84m | 9.11% |
| Simplex Asset Management Co., Ltd.as of 04 Apr 2024 | 87.00k | 0.28% |
Data from 31 Mar 2024 - 09 May 2024Source: FactSet Research Systems Inc.
